Further expansion for Aesica subsidiary R5
New analytical chemistry lab to be built at Biocity in Nottingham
Aesica Pharmaceuticals subsidiary company, R5 Pharmaceuticals, which was acquired by Aesica in June 2010, is set to double in size by the end of the year.
As a result, new facilities will be built to R5’s specification at its site at Biocity in Nottingham. A new analytical chemistry laboratory will be built this spring with the second stage of construction completing in the second half of the year.
Widely acknowledged as one of the leading providers of pharmaceutical dosage form development across Europe, R5 develops and manufactures new medicines and clinical trial materials. The expansion is strategically essential for the company and follows a period of increased demand from existing clients and significant growth in new markets, notably in the US.
‘This is an exciting development for R5 and demonstrates our commitment to evolving and enhancing our service offering to meet market demands,’ said Paul Titley, managing director of R5 Pharmaceuticals. ‘That we are set to double the size of our site and create new facilities, which will enable us to introduce new services to our current provision, is testament to the dedication and expertise of the entire team in establishing R5 as a leader in its field.
‘Becoming part of Aesica in 2010 has proved invaluable and our expansion is largely due to its confidence in our service offering as well as its desire to help us enhance our facilities and establish a presence in new markets.
‘As part of Aesica we aim to promote and further develop our offering, while supporting continued growth as Aesica strives to become the leading provider of formulated products and active pharmaceutical ingredients to the global pharma and biotechnology industries.’
Aesica is one of the UK’s fastest growing companies and is currently undergoing a period of significant and rapid expansion both in the UK and Europe, as well as across America. The R5 expansion follows Aesica’s announcement in December 2010 that it had acquired three manufacturing sites in Europe, almost doubling its workforce.
Aesica supplies contract development and contract manufacturing services for formulated products and active pharmaceutical ingredients to a host of the world’s leading pharmaceutical companies and emerging biotechnology organisations.
Its unique proposition lies in its flexible and bespoke approach to service delivery, coupled with its ability to develop products from the initial clinical stage through to final commercial supply. Furthermore, the long established and proven expertise within the company enables it to provide primary and secondary contract manufacturing services to the highest possible standards. It is this all-encompassing offer and its dedication to exceptional standards of service that truly set Aesica apart from its counterparts.
